WHO ‘Strongly Advises Against’ Use of 2 Antibody COVID Treatments

- Advertisement -

The two COVID-19 antibody treatments are no longer recommended by the World Health Organization because the latest offshoots of Omicron and Variant may have made them obsolete.

- Advertisement -

The two treatments – which are designed to work by binding to the virus’s spike protein to neutralize its ability to infect cells – were some of the first drugs developed at the start of the pandemic.

The virus has evolved since then, and mounting evidence from laboratory tests suggests that two treatments, sotrovimab and casirivimab-imdevimab, have limited clinical activity against the latest iterations of the virus. As a result, they have also fallen out of favor with the US health regulator.


On Thursday, WHO experts said they strongly advised against the use of the two treatments in patients with COVID-19, reversing previous conditional recommendations, as part of a suite of recommendations published to them. british medical journal,

GSK and partner Vir Biotechnology’s sotrovimab, which has generated billions in sales and became one of GSK’s top sellers last year, was taken off the US market by the US Food and Drug Administration in April.

- Advertisement -

Given that the United States began to question the clinical effectiveness of sotrovimab against Omicron in early February, WHO’s receipt is a bit late, said Penny Ward, Pharmaceutical Medicine at King’s College London. Professor in.

“It will be interesting to see how many other countries align with the WHO recommendation”, she said.

Regeneron and partner Roche’s antibody cocktail casirivimab-imdevimab has also sold billions and was one of the US drugmaker’s top sellers last year.

Back in January, the FDA revised its stance on the treatment, limiting its use to a small group of patients, citing its low potency against the Omron version.

Both treatments are recommended for use by the European medicines regulator.

Another COVID-19 therapy that emerged early in the pandemic was Gilead’s antiviral remdesivir. The WHO lowered its conditional recommendation for the drug, advising that it be used only in patients with severe COVID-19 because of its “modest” benefit.

A handful of existing COVID-19 treatments are useful in the fight against the virus, and others in development are expected to benefit patients as well.

Source: www.voanews.com

- Advertisement -

Recent Articles

Related Stories